Last reviewed · How we verify
NCT02573272
Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
trial testing eslicarbacepine in Epilepsy in 204 participants. Status unknown.
1 July 2016
Quick facts
| Lead sponsor | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 204 |
| Start date | 1 June 2015 |
| Primary completion | 1 July 2016 |
| Estimated completion | 1 October 2016 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- eslicarbacepine — full drug profile →
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud — full company profile →
Who can join
18 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Carotid IMT millimeters
Time frame: one year
Sponsor's own description
Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on cardiovascular risk factors measured by biochemical and ultrasound parameters compared with enzyme-inducing AEDs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02573272
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud trials
Trials by the same sponsor.
- NCT04630288 — Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome · unknown
- NCT02687646 — Clinical Trial With MSC for Graft Versus Host Disease Treatment · Phase 1, PHASE2 · completed
- NCT02290041 — Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response · Phase 1, PHASE2 · completed
- NCT01765244 — Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanc · Phase 1, PHASE2 · completed
- NCT02033278 — Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in P · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02573272 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
- Last refreshed: 8 October 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02573272.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing